Loading clinical trials...
Loading clinical trials...
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technolog...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Epiliquid Holding, Inc
NCT07267806 · Hepato Cellular Carcinoma (HCC), Chemotherapy Effect
NCT06960954 · Hepato Cellular Carcinoma (HCC), Portal Vein Tumour Thrombosis
NCT06812039 · Hepato Cellular Carcinoma (HCC)
NCT06742424 · Hepato Cellular Carcinoma (HCC)
NCT07328009 · Hepato Cellular Carcinoma (HCC)
Epiliquid
Mendoza
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions